Mateen Ahmed, MD
Pulmonary Disease · Somerset, KYNPI 1922028604
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,064 of the $14,946 with a category attached, or 80.7%. Intuitive Surgical accounts for 85.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $6,889 and has fallen 68.0% since, to $2,202 in 2025.
Across 142 payments — averaging $105.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- GSK$786
- Mylan Specialty L.p.$263
- AstraZeneca$151
- Sunovion Pharmaceuticals Inc.$118
- Viatris Specialty LLC$111
- plus $731 from 16 others
What the payments were for
- Travel & lodging$6504%
- Food & beverage$2,23215%
- Education$12,06481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $12,787 |
| GSK | 63 | $786 |
| Mylan Specialty L.p. | 16 | $263 |
| AstraZeneca | 10 | $151 |
| Sunovion Pharmaceuticals Inc. | 7 | $118 |
| Viatris Specialty LLC | 6 | $111 |
| ERBE USA Inc | 1 | $100 |
| Galvanize Therapeutics, Inc | 1 | $98 |
| Insmed, Inc. | 6 | $98 |
| Baxter Healthcare | 3 | $75 |
| Grifols USA, LLC | 3 | $75 |
| Amgen | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Tempus AI, Inc | 1 | $23 |
| Inogen, Inc. | 2 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| CSL Behring | 1 | $20 |
| Sanofi | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,764
- ION$3,000
- ErbeCryo2$100
How this compares
$14,946 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $213,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $148,557 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $75,739 |
| Spiriva RespimatTiotropium Bromide | 62 | $38,181 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $23,081 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 396 | $11,950 |
| Arnuity ElliptaFluticasone Furoate | 30 | $10,072 |
| Spiriva HandihalerTiotropium Bromide | 15 | $9,505 |
| Ventolin HfaAlbuterol Sulfate | 137 | $9,036 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,033 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $8,202 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $4,298 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,432 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,967 |
| Roflumilast | 49 | $2,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $75 | $213,76114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $786 | $181,711258 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $151 | $84,772146 claims |
| Boehringer IngelheimSpiriva Respimat | $15 | $38,18162 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $26 | $3,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Somerset
- Sandra SchuldheiszSomerset$225K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
- Josephine MeiLouisville$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.